Function-oriented synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine derivatives as potent PI3K/mTOR dual inhibitors.

[1]  Beibei Mao,et al.  Overview of Research into mTOR Inhibitors , 2022, Molecules.

[2]  Jianyou Shi,et al.  Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment , 2022, Frontiers in Pharmacology.

[3]  J. Burke,et al.  Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yifan Chen,et al.  Research progress of mTOR inhibitors. , 2020, European journal of medicinal chemistry.

[5]  V. Giguère.  DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer. , 2020, Trends in cancer.

[6]  O. Güner,et al.  Akt Pathway Inhibitors. , 2020, Current topics in medicinal chemistry.

[7]  T. Zhu,et al.  Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. , 2020, Journal of medicinal chemistry.

[8]  J. Grandis,et al.  Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. , 2020, Biochimica et biophysica acta. Molecular cell research.

[9]  Michael J. Stocks,et al.  Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. , 2019, Journal of medicinal chemistry.

[10]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[11]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[12]  Yan-hua Fan,et al.  Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors. , 2017, European journal of medicinal chemistry.

[13]  N. Hay,et al.  Akt as a target for cancer therapy: more is not always better (lessons from studies in mice) , 2017, British Journal of Cancer.

[14]  K. Shen,et al.  PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer , 2014, Archives of Gynecology and Obstetrics.

[15]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[16]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[17]  A. González-Angulo,et al.  Targeting the PI3K signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[18]  Sungwoo Hong,et al.  Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis. , 2011, Journal of medicinal chemistry.

[19]  Kaushik Raha,et al.  Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. , 2010, ACS medicinal chemistry letters.

[20]  F. Natt,et al.  Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. , 2008, Cell metabolism.

[21]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[22]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[23]  G. Panayotou,et al.  Phosphoinositide 3-kinases: a conserved family of signal transducers. , 1997, Trends in biochemical sciences.

[24]  L. Cantley,et al.  Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate , 1988, Nature.